# US 2026/0224633 A1 · Pharmaceutical composition for transnasal administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0224633 A1
- Document ID: US20260224633A1
- Status: Published application
- Kind: A1
- Application number: 19/148,976
- Filed: 2024-01-18
- Published: 2026-08-06
- Earliest claimed: 2023-01-18
- Assignees: Daicel Corporation; National University Corporation Hokkaido University
- Applicants: Daicel Corporation; National University Corporation Hokkaido University
- Inventors: Seiichi UCHIMURA; Shuji NAKATSUKA; Masahito KAWABORI
- Web page: https://patentgrep.com/patent/US20260224633A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 9/0043: {Nose}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61P 25/00: Drugs for disorders of the nervous system
- B01D 15/34: Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- B01D 15/363: {Anion-exchange}
- B01D 61/145: {Ultrafiltration}
- B01D 61/16: Feed pretreatment
- B01D 63/02: Hollow fibre modules
- B01D 71/10: Cellulose; Modified cellulose
- A61K 47/38: Cellulose; Derivatives thereof
- B01D 15/3847: {Multimodal interactions}
- B01D 2315/10: Cross-flow filtration
- B01D 2325/36: Hydrophilic membranes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

The purpose of the present disclosure is to provide a pharmaceutical composition having an excellent therapeutic effect for the treatment of a central nervous system disease. The pharmaceutical composition for transnasal administration contains a purified extracellular vesicle product and is used for treating a central nervous system disease. The purified extracellular vesicle product is obtained by a method for producing a purified extracellular vesicle product, with the method including: (i) purifying a liquid to be treated and containing extracellular vesicles and an impurity by bringing the liquid into contact with an exclusion and anion exchange carrier to obtain a treated liquid containing the extracellular vesicles; and (ii) subjecting the treated liquid to membrane filtration to obtain a concentrate of the extracellular vesicles. The resulting pharmaceutical composition for transnasal administration exhibits an excellent therapeutic effect for the treatment of a central nervous system disease.

## Claims

### Claim 1

A pharmaceutical composition for transnasal administration, the pharmaceutical composition comprising a purified extracellular vesicle product and being used for treating a central nervous system disease,
the purified extracellular vesicle product being obtained by a method for producing a purified extracellular vesicle product, the production method comprising (i) purification and (ii) membrane filtration:
(i) purifying a liquid to be treated, the liquid containing extracellular vesicles and an impurity, by bringing the liquid into contact with an exclusion and anion exchange carrier to obtain a treated liquid containing the extracellular vesicles; and
(ii) subjecting the treated liquid to membrane filtration to obtain a concentrate of the extracellular vesicles.

### Claim 2 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein the central nervous system disease is hypoxic encephalopathy.

### Claim 3 (depends on 2)

The pharmaceutical composition for transnasal administration according to claim 2, wherein the hypoxic encephalopathy is global cerebral ischemia.

### Claim 4 (depends on 2)

The pharmaceutical composition for transnasal administration according to claim 2, wherein the pharmaceutical composition comprises the extracellular vesicles at an amount of 1×103 extracellular vesicles/μL or more.

### Claim 5 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein the liquid to be treated is a culture supernatant of cells or a tissue thereof that secretes the extracellular vesicles.

### Claim 6 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein the exclusion and anion carrier is a porous carrier having internally positively charged pores.

### Claim 7 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein a membrane used for the membrane filtration has a molecular weight cutoff of from 100000 to 1000000.

### Claim 8 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein a membrane used for the membrane filtration has a γ-globulin permeability of from 10% to 80%.

### Claim 9 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein a membrane used for the membrane filtration has a pure water permeation flow rate at 0.1 MPa of from 500 to 1500 L/m2/Hr.

### Claim 10 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein a membrane used for the membrane filtration is a cellulose-based hydrophilic membrane.

### Claim 11 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein a membrane used for the membrane filtration is a hollow fiber membrane.

### Claim 12 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein the membrane filtration is tangential flow filtration.

### Claim 13 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein a membrane surface velocity in the membrane filtration is from 0.3 m/sec to 2 m/sec.

### Claim 14 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein a concentration of the extracellular vesicles contained in the concentrate of the extracellular vesicles is 10 or more times a concentration of the extracellular vesicles contained in the treated liquid.

### Claim 15 (depends on 1)

The pharmaceutical composition for transnasal administration according to claim 1, wherein a concentration of total protein contained in the concentrate of the extracellular vesicles is 0.3 or less times a concentration of total protein contained in the liquid to be treated.

### Claim 16

A method for producing a pharmaceutical composition for transnasal administration for treating global cerebral ischemia, the production method comprising:
(i) purifying a liquid to be treated, the liquid containing extracellular vesicles and an impurity, by bringing the liquid into contact with an exclusion and anion exchange carrier to obtain a treated liquid containing the extracellular vesicles; and
(ii) subjecting the treated liquid to membrane filtration to obtain a concentrate of the extracellular vesicles.
